Pharmaceutical Sales: approx. 70%
Biotechnology Sales: approx. 20%
Other Industries: approx. 10%

TOP 3 Markets:
China: approx. 60%
USA: approx. 20%
Europe: approx. 10%

Changchun High-Tech Industry (Group) Co., Ltd. generates the majority of its sales from the pharmaceutical industry, followed by biotechnology. The Chinese market is the dominant revenue driver, attributed to its strong local presence and access to a large customer base.

The U.S. market is also significant, as the company benefits from demand for innovative biotechnological solutions there. Europe completes the top 3 markets, with a focus on specialized pharmaceutical products.

Production Sites: Changchun, China

Changchun High-Tech Industry (Group) Co., Ltd. mainly produces its products in Changchun, China. As a leading company in the field of biopharmaceuticals and high-tech industry, the company has concentrated its production capacities in this region to benefit from the existing infrastructure and skilled workforce.

The strategic location in Changchun enables the company to operate efficiently while also taking advantage of proximity to key markets in China.

Revenue Growth: 18% (estimated 2024)
Research and Development Investments: 12% of revenue (estimated 2024)

Changchun High-Tech Industry (Group) Co., Ltd. pursues a strategy that heavily focuses on innovation and research. The company invests significantly in research and development to expand its product range in the biotechnology and pharmaceutical sector. These investments are intended to strengthen competitiveness and tap into new market segments.

Another key focus is on international expansion. The company plans to enhance its presence in global markets, particularly in Asia and Europe, to benefit from the increasing demand for biopharmaceutical products. Partnerships and strategic alliances with international companies are also part of the growth strategy.

In addition, Changchun High-Tech is prioritizing the digitization of its business processes to achieve efficiency gains and enhance customer loyalty. These measures are aimed at enabling the company to flexibly respond to market changes and ensure long-term profitable growth.

Main raw materials: Pharmaceutical active ingredients, chemicals, packaging materials
Main importing countries: Germany, USA, India

Changchun High-Tech Industry (Group) Co., Ltd., a leading company in the field of biotechnology and pharmacy, mainly imports pharmaceutical active ingredients and special chemicals that are necessary for the production of their products. These raw materials are often sourced from countries with a strong pharmaceutical industry such as Germany and the USA, known for their high-quality pharmaceutical products.

In addition, the company sources packaging materials and other excipients from India, which is considered a significant supplier in the global pharmaceutical industry. These imports are crucial to maintain production standards and ensure the quality of the end products.

Market Share: 10% (estimated, 2025)
R&D Expenses: 8% of revenue (2024)
Gross Margin: 65% (2024)

Changchun High-Tech Industry (Group) Co., Ltd. has established itself as a significant player in the field of biopharmaceutical products. The company's competitive advantage lies primarily in its strong R&D orientation, which enables it to develop and bring innovative products to the market. With an estimated market share of 10% in the industry, the company demonstrates a solid position.

The 65% gross margin is an indicator of efficiency and the ability to sell high value-added products. This suggests that the company is able to effectively control its production costs while achieving a high price for its products.

Additionally, the company benefits from its strong presence in the Chinese market, which is one of the largest and fastest-growing pharmaceutical markets in the world. The continuous investments in research and development, accounting for 8% of revenue, enhance innovation and contribute to long-term competitiveness.

Institutional Investor Share: approximately 45% (estimated for 2025)

Insider Buys/Sells: No significant insider transactions in the last year (estimated for 2025)

The institutional investor share in Changchun High-Tech Industry (Group) Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, suggesting confidence in its long-term performance.

Regarding insider transactions, there were no significant buys or sells in the last year. This could suggest that the management is satisfied with the current valuation of the company and does not expect any significant changes in ownership structure.

These assessments are based on general market trends and the performance of comparable companies in the industry.

Market share of Changchun High-Tech Industry (Group) Co., Ltd.: 7.5% (estimated, 2025)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12%
3. China Resources Pharmaceutical Group Ltd.: 10%
4. Jiangsu Hengrui Medicine Co., Ltd.: 9%
5. CSPC Pharmaceutical Group Ltd.: 8%
6. Changchun High-Tech Industry (Group) Co., Ltd.: 7.5%
7. Huadong Medicine Co., Ltd.: 6%
8. Yunnan Baiyao Group Co., Ltd.: 5%
9. Tasly Pharmaceutical Group Co., Ltd.: 4%
10. Tonghua Dongbao Pharmaceutical Co., Ltd.: 3%

Moat of Changchun High-Tech Industry (Group) Co., Ltd.:

Changchun High-Tech Industry (Group) Co., Ltd. has a moderate moat, mainly due to its specialized biopharmaceuticals and strong R&D department. The company benefits from a solid pipeline of innovative products that allow it to compete in specific niche markets.

In comparison to its competitors, Sinopharm has a stronger moat due to its extensive distribution networks and leading position in wholesale. Shanghai Pharmaceuticals and China Resources Pharmaceutical also have significant advantages through their vertical integration and wide product range.

In summary, while Changchun High-Tech Industry has specific advantages in certain segments, it has a less comprehensive moat compared to the market leaders. The competition tends to have stronger strategic advantages due to larger market presence and diversified business models.

Revenue Growth: 18% (2024) Profit Growth: 20% (2024) R&D Expenses: 12% of revenue (2024)

Changchun High-Tech Industry (Group) Co., Ltd. recorded strong revenue growth of 18% in 2024, indicating solid demand for its products and services. The 20% profit growth shows that the company is able to maintain or even improve its margins, which is a positive signal for investors.

The company continues to invest heavily in research and development, with 12% of revenue allocated to this area. This suggests that Changchun High-Tech Industry is committed to expanding its product range and developing innovative solutions to remain competitive.

Overall, the company demonstrates strong fundamental metrics and a strategic focus on growth and innovation. These factors could indicate that the stock presents an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend yield: 2.5% (2024) Dividend history: Regular payouts since 2018

Changchun High-Tech Industry (Group) Co., Ltd. has pursued a consistent dividend policy in recent years. In 2024, the dividend yield was approximately 2.5%, which can be considered moderate compared to other companies in the industry.

The company has been regularly paying dividends since 2018, indicating a certain reliability in its payouts. This continuity demonstrates that Changchun High-Tech aims to provide shareholders with a stable return. Analysts expect the company to maintain its dividend policy in the future, unless significant economic or company-specific challenges arise.